@article {360,
	title = {Drug Review: Daridorexant},
	journal = {International Journal of Pharmacology and Clinical Sciences},
	volume = {12},
	year = {2023},
	month = {September 2023},
	pages = {90-91},
	type = {Research Article},
	chapter = {90},
	abstract = {<p class="rtejustify">Registrations: had been registered in the following countries United States of America (USA), United Kingdom (U.K.), Canada, and Saudi Arabia (SA). Trade name (USA.); QUVIVIQ{\textregistered} Registration number (S.A.); Not Available. Insurance Drug Formulary (S.A.); Not covered (28.1.2023). General Information: Registered Company: Idorsia Pharmaceuticals, Ltd. Regulatory Status: R.X. Mechanism of Action: The treatment of insomnia is presumed to be through the antagonism of orexin receptors. In addition, the orexin neuropeptide signaling system plays a role in wakefulness. Blocking the binding of wake-promoting neuropeptides orexin A and orexin B to receptors OX1R and OX2R is thought to suppress wake drive. <strong>Read more...</strong></p>
},
	doi = {10.5530/ijpcs.2023.12.11},
	author = {Juman Alsaab}
}
